Evidence map›Paper›PMID 20586814›Full record

ArticleInternational journal of experimental pathology2010

Establishment and characterization of a murine xenograft model of appendiceal mucinous adenocarcinoma.

Arun A Mavanur, Vamsi Parimi, Mark O'Malley, Marina Nikiforova, David L Bartlett, Jon M Davison

Abstract read
In one paragraph

Article in International journal of experimental pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  4. Improved chemosensitivity following mucolytic therapy in patient-derived models of mucinous appendix cancer.Translational research : the journal of laboratory and clinical medicine · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Arun A MavanurDepartment of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Vamsi Parimi
Mark O'Malley
Marina Nikiforova
David L Bartlett
Jon M Davison

Funding

Postdoctoral Research Training in Biotherapy of CancerT32CA113263 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Udai S Kammula · 2006 to 2026
$3.6M
NCI NIH HHS T32 CA113263
6 · The paper itself

Abstract

We describe the clinical, pathologic and molecular characteristics of a xenograft model of metastatic mucinous appendiceal adenocarcinoma. Tumours from patients with mucinous appendiceal neoplasms were implanted in nude mice and observed for evidence of intraperitoneal tumour growth. Morphologic and immunohistochemical features, temporal growth characteristics relative to controls, and loss of heterozygosity (LOH) at multiple chromosomal alleles were assessed in a successfully engrafted tumour. Two of seventeen implanted tumours successfully engrafted and only one mucinous adenocarcinoma propagated throughout the course of the study. The successful xenograft is morphologically similar to the original tumour, produces abundant extracellular mucin and exhibits non-invasive growth on peritoneal surfaces. The temporal growth characteristics of the xenograft tumour relative to controls reveal that tumour burden can be followed indirectly by measuring the weight or abdominal girth of engrafted animals. The cytokeratin, mucin core protein, CDX2, Ki-67 and p53 expression patterns are identical in the xenograft and resected tumour and are consistent with the expected pattern of protein expression for mucinous adenocarcinoma of the appendix. LOH was found in 1 of 10 informative chromosomal loci (chromosome 10p23) in xenograft tumour cells. Although we were unable to engraft a low-grade appendiceal mucinous neoplasm, the engrafted adenocarcinoma will be useful for future evaluation of novel therapeutic strategies directed at mucinous appendiceal adenocarcinoma and evaluation of strategies for treating widespread, bulky, mucinous peritoneal surface neoplasms. Xenograft tumour enrichment can facilitate molecular studies of appendiceal epithelial neoplasia.

Indexed as

Xenograft Model Antitumor AssaysAdenocarcinoma, MucinousAnimalsAppendiceal NeoplasmsCDX2 Transcription FactorCell ProliferationChromosomes, Human, Pair 10Gene Expression Regulation, NeoplasticHomeodomain ProteinsHumansKeratinsKi-67 AntigenLoss of HeterozygosityMiceMice, NudeMucinsCDX2 protein, humanCDX2 Transcription FactorHomeodomain ProteinsKeratinsKi-67 AntigenKRAS protein, humanMucinsProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)ras ProteinsTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID20586814
PMCPMC2962894

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.